Search Results
Your search for all items matches 64 pages
Showing 1 - 50
Cara Norelli, MS, AGNP-C, on Managing Dermatologic Side Effects in Patients With Cancer
Cara Norelli, MS, AGNP-C, of Memorial Sloan Kettering Cancer Center, discusses her presentation on dermatologic toxicities seen in patients with cancer from the JADPRO Live conference recently held in Grapevine, Texas. Ms. Norelli covers the importance of knowing the distinguishing characteristics...
Justin Arnall, PharmD, BCOP, FCCP, on Complicating “Factors”: When Malignancy and Non-Malignant Hematology Collide
Justin Arnall, PharmD, BCOP, FCCP, of Atrium Health Specialty Pharmacy Service in Charlotte, North Carolina, discusses his JADPRO Live presentation on critical considerations when planning for cancer-related procedures in patients with hereditary/congenital as well as acquired bleeding disorders.
Wendy Vogel, MSN, FNP, AOCNP, FAPO, on the Evolving Role of Advanced Practice Providers in Oncology Care
Wendy Vogel, MSN, FNP, AOCNP, FAPO, of the Advanced Practitioner Society for Hematology and Oncology, summarizes a panel discussion in which she took part, on forming interprofessional oncology care teams that include advanced practitioners. Such collaboration may improve patient outcomes and help...
Enrique Grande, MD, on Adrenocortical Carcinoma: Phase II Results on Cabozantinib Plus Atezolizumab
Enrique Grande, MD, of MD Anderson Cancer Center Madrid, discusses findings from the CABATEN/GETNE-T1914 study, in which cabozantinib plus atezolizumab showed modest activity in patients with locally advanced or metastatic adrenocortical carcinoma, a rare malignancy with a poor prognosis and...
Funda Meric-Bernstam, MD, on HER2-Expressing Solid Tumors: Efficacy and Safety of Trastuzumab Deruxtecan
Funda Meric-Bernstam, MD, of The University of Texas MD Anderson Cancer Center, discusses interim results from the DESTINY-PanTumor02 trial, the first tumor-agnostic global study of fam-trastuzumab deruxtecan-nxki (T-DXd) in a broad range of HER2-expressing solid tumors. This agent showed an...
Christina M. Dieli-Conwright, PhD, MPH, on Resistance Exercise as Medicine: Improving Health and Cancer Outcomes
Christina M. Dieli-Conwright, PhD, MPH, of Dana-Farber Cancer Institute, discusses her research on the ways in which postdiagnosis exercise, particularly resistance exercise, can build strength and muscle mass and affect cancer outcomes. She also describes her focus on biomarkers related to body...
Timothy A. Yap, MD, PhD, on New Findings on Treating Solid Tumors With PARP and ATR Inhibitors
Timothy A. Yap, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses safety and efficacy data on three different PARP inhibitors combined with the ATR inhibitor camonsertib in patients with solid tumors harboring DNA damage response alterations. The findings showed that low-dose ...
Diana Azzam, PhD, on Pediatric Cancers: Efficacy of a Precision Medicine Approach
Diana Azzam, PhD, of Florida International University, Robert Stempel College of Public Health and Social Work, discusses her study results, which showed that treatment protocols guided by functional precision medicine yielded significantly longer progression-free survival and improved overall...
Mitesh J. Borad, MD, on Hepatobiliary Cancers: Management Updates
Mitesh J. Borad, MD, of the Mayo Clinic Comprehensive Cancer Center, discusses the expanding number of options in immunotherapies for patients with advanced hepatobiliary cancers, applying targeted treatments to this disease, and the importance of genomic profiling in patients with biliary tract...
Arlene O. Siefker-Radtke, MD, on Urothelial Cancer: Emerging Therapies
Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, provides an overview of the emerging treatments for urothelial cancer, including several new agents in the antibody-drug conjugate and tyrosine kinase inhibitor classes. She describes the clinical activity and...
Ella A. Kazerooni, MD, on Lung Cancer Screening: Benefits and Challenges
Ella A. Kazerooni, MD, of the University of Michigan Rogel Cancer Center, discusses reducing cancer deaths in the United States by identifying patients at risk for lung cancer. Engaging with primary care physicians and facilitating referrals are keys to a successful lung cancer screening program,...
Midhun Malla, MD, on Metastatic Colorectal Cancer: Treatment Updates
Midhun Malla, MD, of the West Virginia University Cancer Institute, discusses the molecular landscape of metastatic colorectal cancer and the development and approvals of targeted treatments. Dr. Malla also details the range of HER2-targeted therapeutic options and the approval of trastuzumab and...
Louis B. Nabors, MD, on NCCN Clinical Practice Guidelines in Oncology Updates for CNS Cancers in Adults
Louis B. Nabors, MD, of the O’Neal Comprehensive Cancer Center at UAB, discusses the three subtypes of adult gliomas classified by the World Health Organization, treatments influenced by IDH mutation status, the roles of radiotherapy and chemotherapy, molecular testing, and pseudoprogression and...
Antoni Ribas, MD, PhD, on Solid Tumors: Safety and Efficacy of TCR T-Cell Therapy
Antoni Ribas, MD, PhD, of the University of California, Los Angeles, discusses a phase I study that used CRISPR gene editing to simultaneously “knock out” endogenous T-cell receptors and replace them with personalized neoantigen T-cell receptors in patients with solid tumors. The edited TCR T-cell...
Bernd Kasper, MD, PhD, on Desmoid Tumors: Results on Nirogacestat vs Placebo
Bernd Kasper, MD, PhD, of Germany’s Mannheim Cancer Center, discusses phase III data from the DeFi trial, the largest study conducted to date for patients with desmoid tumors. The trial showed that the gamma secretase inhibitor nirogacestat demonstrated improvements in all primary and secondary...
Timothy A. Yap, MBBS, PhD, on Advanced Solid Tumors With DNA Damage Response Defects: Early Data on Elimusertib
Timothy A. Yap, MBBS, PhD, of The University of Texas MD Anderson Cancer Center, discusses results from a phase Ib expansion trial of the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumors with DNA damage response defects....
Josh Neman, PhD, on Brain Metastasis: A Neuroscience Perspective
Josh Neman, PhD, of the Keck School of Medicine, University of Southern California, discusses the distribution of brain metastasis to preferential brain regions that vary according to cancer subtype, how neurotransmitters respond, and the ways in which the central nervous system acclimates...
John B.A.G. Haanen, MD, PhD, on Solid Tumors: Early Study Results on CAR T Cells and the CARVac Vaccine Strategy
John B.A.G. Haanen, MD, PhD, of the Netherlands Cancer Institute, discusses findings from a phase I study designed to test the safety and efficacy of the CARVac (CAR-T cell-amplifying RNA vaccine) strategy to overcome poor CAR T-cell stimulation and responses in patients with CLDN6-positive...
Alfredo Berruti, MD, on Adrenocortical Carcinoma: Preliminary Study Results With Adjuvant Mitotane
Alfredo Berruti, MD, of Italy’s University of Brescia, discusses the first study to give adjuvant mitotane to patients with adrenocortical carcinoma, a rare disease with a high risk of relapse after radical surgery. Although theoretically this treatment may be clinically worthwhile, the findings...
Hielke-Martijn de Vries, MD, on Penile Cancer: New Data on Atezolizumab and Radiotherapy
Hielke-Martijn de Vries, MD, of the Netherlands Cancer Institute, discusses phase II findings on the use of atezolizumab with or without radiotherapy for patients with advanced squamous cell carcinoma of the penis. The study was designed to address the poor prognosis for this disease by exploring...
Mehmet Altan, MD, on Solid Tumors: Interim Safety and Efficacy Results on NKTR-255 Plus Cetuximab
Mehmet Altan, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from a phase Ib dose-escalation study, which showed early evidence of activity for NKTR-255, an investigational IL-15 receptor agonist, plus cetuximab in patients with solid tumors. Treatment appeared to lead ...
Kim A. Reiss, MD, on HER2-Overexpressing Solid Tumors: First-in-Human Study of Anti-HER2 CAR Macrophages
Kim A. Reiss, MD, of the University of Pennsylvania, discusses results of a phase I trial of a CAR-M engineered macrophage cancer therapy, known as CT-0508, for patients with solid tumors that overexpress HER2. CAR-M, designed to exploit the natural role of macrophages to initiate an antitumor...
Aadel A. Chaudhuri, MD, PhD, on Personalizing Treatment for Oligometastatic Cancer
Aadel A. Chaudhuri, MD, PhD, of Washington University School of Medicine in St. Louis, discusses circulating tumor DNA, which has the potential to better personalize treatment for patients with oligometastatic cancer and help clinicians determine whether to offer systemic therapy alone or...
Robert A. Olson, MD, on Oligometastases: New Data on Stereotactic Ablative Radiotherapy
Robert A. Olson, MD, of the University of British Columbia, discusses phase II findings from the SABR-5 trial on stereotactic ablative radiotherapy for up to five oligometastases. Although toxicity of liver and adrenal metastases warrants caution, the trial seemed to show that this type of...
Carey K. Anders, MD, on Brain Metastases: Integrating Immunotherapy Into Clinical Care
Carey K. Anders, MD, of the Duke Cancer Center, discusses the ways in which treatment of brain metastases arising from solid tumors has moved into a new era of patient care and how the field may advance.
Vivek Subbiah, MD, on RET Fusion–Positive Cancers: Efficacy of Selpercatinib
Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses data on selpercatinib that showed promising activity across a variety of RET fusion–positive cancers, including treatment-refractory gastrointestinal malignancies. This analysis highlights the need for genomic...
Prasad S. Adusumilli, MD, on Cell Therapy for Solid Tumors
Prasad S. Adusumilli, MD, of Memorial Sloan Kettering Cancer Center, discusses ongoing CAR T-cell therapy clinical trials for solid tumors, the key determinants of success for developing this treatment, and some study results to date (Abstract PL03.05).
Thierry André, MD, on Mismatch Repair–Deficient Solid Cancers: Safety and Efficacy of Dostarlimab
Thierry André, MD, of Hôpital Saint-Antoine, discusses results from the GARNET study, which showed that dostarlimab, an anti–PD-1 antibody, demonstrated durable antitumor activity in patients with mismatch repair–deficient colorectal and noncolorectal solid tumors. No new safety signals were...
Nickolas Papadopoulos, PhD, on Liquid Biopsy to Screen for Multiple Cancer Types
Nickolas Papadopoulos, PhD, of Johns Hopkins Medicine, discusses a first-of-its-kind prospective study that evaluated a screening blood test in more than 10,000 older women with no history of cancer. The test, called DETECT-A, identified 10 different cancer types, 65% of which were early-stage...
Ryan J. Sullivan, MD, on Advanced Solid Tumors: Antitumor Activity With COM701 Plus Nivolumab
Ryan J. Sullivan, MD, of Massachusetts General Hospital Cancer Center, discusses early results on COM701, a first-in-class immune checkpoint inhibitor, which showed preliminary antitumor activity as a monotherapy and in combination with nivolumab in a variety of heavily pretreated patients with...
Hope S. Rugo, MD, on Talazoparib for Advanced Solid Tumors: Reduced Hospitalization and Supportive Care
Hope S. Rugo, MD, of the University of California, San Francisco, discusses an integrated analysis of five clinical trials, in phases I through III, for a variety of advanced cancers. Findings show that patients treated with talazoparib monotherapy had lower hospitalization rates (compared to those ...
Alejandra Méndez Romero, MD, PhD, on Liver Metastases: Dutch-Belgian Registry of Stereotactic Body Radiation
Alejandra Méndez Romero, MD, PhD, of Erasmus University Medical Center, discusses findings that show high local control rates with stereotactic body radiation for patients in this large published series, most of whom had colorectal cancer (Abstract 230).
Daniel M. Trifiletti, MD, on Optimizing Whole-Brain Radiotherapy Dose and Fractionation for Patients With Brain Metastases
Daniel M. Trifiletti, MD, of the Mayo Clinic, discusses study findings showing that, between two different radiation doses (30 Gy/10 fractions vs 37.5 Gy/15 fractions), there was no difference in the time to cognitive failure, tumor control, or overall survival for patients with brain metastases...
Hani M. Babiker, MD, on Tumor Treating Fields: A Different Approach to Therapy
Hani M. Babiker, MD, of the The University of Arizona, discusses an emerging treatment that inhibits the mitotic spindle and disrupts tumor cell growth. The method has been approved by the FDA to treat some cancers and data show improved progression-free and overall survival (Abstracts 2055, 8551,...
Christopher Sweeney, MBBS, and Ian D. Davis, MBBS, PhD, on ANZUP: Taking a Multidisciplinary Approach to Prostate, Kidney, Bladder, Testicular, and Penile Cancers
Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, and Ian D. Davis, MBBS, PhD, of Monash University and Eastern Health, discuss the Australian and New Zealand Urogenital and Prostate Cancer Trials Group, working globally to speed clinical research in and treatment of urogenital cancers.
Brian C. Baumann, MD, on Locally Advanced Cancer: Proton vs Photon Therapy
Brian C. Baumann, MD, of Washington University School of Medicine, discusses study findings that showed, for adults with locally advanced cancer across five different disease sites, proton chemoradiotherapy was associated with significantly reduced acute adverse events, with no difference in...
Sarah Abou Alaiwi, MD, and Toni K. Choueiri, MD, on Checkpoint Inhibitors: Overall Survival and Polybromo-Associated Mutations
Toni K. Choueiri, MD, and Sarah Abou Alaiwi, MD, both of Dana-Farber Cancer Institute, discuss the association of polybromo-associated BAF-type mutations with overall survival in patients with different solid tumors treated with checkpoint inhibitors (Abstract 103).
Craig R. Nichols, MD, on Testicular Cancer Cases: Should They Be Discussed With High-Volume Centers?
Craig R. Nichols, MD, of the Testicular Cancer Commons and the SWOG Group Chair's Office, discusses the superior outcomes obtained at high-volume centers, the impracticality of referring all patients to such centers, and the international efforts to develop virtual collaborations on salvage...
Stefanie C. Fischer, MD, on Nonseminoma: Outcomes After Adjuvant Bleomycin/Etoposide/Cisplatin
Stefanie C. Fischer, MD, of Manchester Cancer Research Centre and The Christie NHS Foundation Trust, discusses an international retrospective analysis of the rare clinical scenario of men relapsing after adjuvant treatment with bleomycin/etoposide/cisplatin for clinical stage I nonseminoma...
David Palma, MD, PhD, on Oligometastatic Tumors: Results From the SABR-COMET Trial
David Palma, MD, PhD, of the London Health Sciences Centre, discusses study findings on improvement in survival following stereotactic ablative radiation for oligometastatic tumors (Presentation 5 in PL 01).
Lalan S. Wilfong, MD, on Metastatic Solid Tumors: Limiting Low-Value Care
Lalan S. Wilfong, MD, of Texas Oncology, discusses reducing the use of a white blood cell growth factor treatment in advanced and incurable solid tumors for patients treated at a community oncology practice.
Apostolia-Maria Tsimberidou, MD, PhD, on Precision Medicine: Results From the IMPACT Study
Apostolia-Maria Tsimberidou, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses findings on clinical outcomes, including long-term survival, according to the pathway targeted and treatment period (Abstract LBA2553).
Jeffrey M. Holzbeierlein, MD, on Penile, Urethral, and Testicular Cancers: Abstract Roundup
Jeffrey M. Holzbeierlein, MD, of the University of Kansas Medical Center, summarizes key abstracts on long-term sexual function in germ cell tumor survivors, sentinel node biopsy in clinical stage I testicular cancer, the impact of Medicaid expansion on diagnosis and management of patients with...
Linda Mileshkin, MBBS, on Solid Tumors: Early Treatment Study Results
Linda Mileshkin, MBBS, of the Peter MacCallum Cancer Centre, discusses phase Ib trial findings on the anti–PD-1 monoclonal antibody BGB-A317 in combination with the PARP inhibitor BGB-290 in advanced solid tumors.
Jeffrey M. Lemons, MD, on Solid Tumors: Safety Data on SBRT and Immunotherapy
Jeffrey M. Lemons, MD, of the University of Chicago, discusses early safety and efficacy findings from a small study on pembrolizumab and multiorgan-site ablative stereotactic body radiotherapy in patients with advanced solid tumors (Abstract 20).
David M. Hyman, MD, on Larotrectinib in TRK Fusion Cancers: Trial Results
David M. Hyman, MD, of Memorial Sloan Kettering Cancer Center, discusses findings on the efficacy of larotrectinib, a selective tropomyosin receptor kinase inhibitor, in adult and pediatric cancers. (Abstract LBA2501)
Shridar Ganesan, MD, PhD, on Mutation Burden and Immunotherapy
Shridar Ganesan, MD, PhD, of the Rutgers Cancer Institute of New Jersey, discusses mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers.
Prasad S. Adusumilli, MD, on Solid Tumors: CAR T Cells and Immune Checkpoint Blockade
Prasad S. Adusumilli, MD, of Memorial Sloan Kettering Cancer Center, discusses a way to promote functional persistence of CAR T cells as an ideal strategy for solid tumor immunotherapy.
Stephen Gottschalk, MD, on CAR T Cells for Solid Tumors: What Are the Challenges?
Stephen Gottschalk, MD, of Baylor College of Medicine and Texas Children’s Hospital, discusses combining CAR T cells with checkpoint blockade or targeted treatments to improve their antitumor activity in solid tumors.
